[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neurosense Therapeutics Ltd WT (NRSNW)

Neurosense Therapeutics Ltd WT (NRSNW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,130 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 06/30/26
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0391 +0.26%
on 08/21/26
0.1599 -75.48%
on 08/03/26
-0.0208 (-34.67%)
since 07/24/26
3-Month
0.0391 +0.26%
on 08/21/26
0.2700 -85.48%
on 06/08/26
-0.0413 (-51.30%)
since 05/22/26
52-Week
0.0391 +0.26%
on 08/21/26
0.6985 -94.39%
on 09/03/25
-0.5308 (-93.12%)
since 08/18/25

Most Recent Stories

More News
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

The planned submission follows alignment with Health Canada on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway...

NRSNW : 0.0392 (-12.11%)
NRSN : 0.3750 (-0.35%)
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NRSNW : 0.0392 (-12.11%)
NRSN : 0.3750 (-0.35%)
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS

CAMBRIDGE, Mass. , June 29, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...

NRSNW : 0.0392 (-12.11%)
NRSN : 0.3750 (-0.35%)
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

CAMBRIDGE, Mass. , June 22, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...

NRSNW : 0.0392 (-12.11%)
NRSN : 0.3750 (-0.35%)
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

CAMBRIDGE, Mass. , June 11, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"  or the "Company"), a late-clinical stage biotechnology company developing novel...

NRSNW : 0.0392 (-12.11%)
NRSN : 0.3750 (-0.35%)
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patents

NRSNW : 0.0392 (-12.11%)
NRSN : 0.3750 (-0.35%)
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements

CAMBRIDGE, Mass. , April 3, 2026 /PRNewswire/ --  NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments...

NRSNW : 0.0392 (-12.11%)
NRSN : 0.3750 (-0.35%)
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference

Dr. Christian Lunetta to Present "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial"

NRSNW : 0.0392 (-12.11%)
NRSN : 0.3750 (-0.35%)
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower functional...

NRSNW : 0.0392 (-12.11%)
NRSN : 0.3750 (-0.35%)
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

CAMBRIDGE, Mass. , March 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...

NRSNW : 0.0392 (-12.11%)
NRSN : 0.3750 (-0.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.